Spyre Therapeutics (SYRE) free cash flow

Free cash flow · fiscal 2025
-$169.25M

Spyre Therapeutics (SYRE) generated free cash flow of -$169.25M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$157.41M. Figures as of 18 Nov 2026, 12:03 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Free cash flow, fiscal 2025
-$169.25M
Highest on record
-$7.52Mfiscal 2014
Lowest on record
-$169.25Mfiscal 2025
Fiscal years on record
122014–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Spyre Therapeutics free cash flow, in more detail

Across the 12 fiscal years on record (2014–2025), the highest was -$7.52M in fiscal 2014 and the lowest -$169.25M in fiscal 2025.

History · 12 fiscal years

Free cash flow by fiscal year

Spyre Therapeutics free cash flow, year by year

Spyre Therapeutics (SYRE) free cash flow by fiscal year
Fiscal yearFree cash flowChangeYear ended
2025-$169.25M—
2024-$157.41M—
2023-$99.91M—
2022-$80.18M—
2021-$54.29M—
2020-$80.06M—
2019-$67.18M—
2018-$32.62M—
2017-$25.23M—
2016-$19.05M—
2015-$11.19M—
2014-$7.52M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.

How to read it

It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.

Free cash flow at health care companies of similar size

Free cash flow of Spyre Therapeutics and comparable companies
CompanyFree cash flowFiscal year
Vaxcyte PCVX-$712.55M2025
Bio-Rad Laboratories BIO$374.60M2025
Molina Healthcare MOH-$636.00M2025
Spyre Therapeutics SYRE-$169.25M2025
Qiagen QGEN$447.20M2025
Insulet PODD$349.90M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on SYRE

Spyre Therapeutics, figure by figure

Spyre Therapeutics (SYRE) overview: price, valuation and scorecardAll health care companies by market value

Spyre Therapeutics free cash flow: questions and answers

What is Spyre Therapeutics's free cash flow?

Spyre Therapeutics (SYRE) generated free cash flow of -$169.25M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$157.41M.

What are the highest and lowest free cash flow figures on record for Spyre Therapeutics?

Across the 12 fiscal years on record (2014–2025), the highest was -$7.52M in fiscal 2014 and the lowest -$169.25M in fiscal 2025.

How is Spyre Therapeutics's free cash flow calculated?

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For Spyre Therapeutics it is on record here for 12 fiscal years, 2014 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Spyre Therapeutics (SYRE) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/SYRE/free-cash-flow

Underlying data: the company's filings with the SEC and Yahoo Finance.